journal

Lancet Oncology

journal
https://read.qxmd.com/read/32645283/cabozantinib-as-a-choice-for-platinum-refractory-metastatic-urothelial-cancer
#1
Eiji Kikuchi, Nozomi Hayakawa
No abstract text is available yet for this article.
July 6, 2020: Lancet Oncology
https://read.qxmd.com/read/32645282/cabozantinib-in-patients-with-platinum-refractory-metastatic-urothelial-carcinoma-an-open-label-single-centre-phase-2-trial
#2
Andrea B Apolo, Rosa Nadal, Yusuke Tomita, Nicole N Davarpanah, Lisa M Cordes, Seth M Steinberg, Liang Cao, Howard L Parnes, Rene Costello, Maria J Merino, Les R Folio, Liza Lindenberg, Mark Raffeld, Jeffrey Lin, Min-Jung Lee, Sunmin Lee, Sylvia V Alarcon, Akira Yuno, Nancy A Dawson, Kimaada Allette, Arpita Roy, Dinuka De Silva, Molly M Lee, Tristan M Sissung, William D Figg, Piyush K Agarwal, John J Wright, Yangmin M Ning, James L Gulley, William L Dahut, Donald P Bottaro, Jane B Trepel
BACKGROUND: Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma. METHODS: This study was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA)...
July 6, 2020: Lancet Oncology
https://read.qxmd.com/read/32593317/carcinogenicity-of-some-aromatic-amines-and-related-compounds
#3
(no author information available yet)
No abstract text is available yet for this article.
June 25, 2020: Lancet Oncology
https://read.qxmd.com/read/32593316/expanding-access-to-radiotherapy-in-sub-saharan-africa
#4
Rebecca Barksby
No abstract text is available yet for this article.
June 25, 2020: Lancet Oncology
https://read.qxmd.com/read/32589866/lenvatinib-plus-pembrolizumab-in-patients-with-advanced-gastric-cancer-in-the-first-line-or-second-line-setting-epoc1706-an-open-label-single-arm-phase-2-trial
#5
Akihito Kawazoe, Shota Fukuoka, Yoshiaki Nakamura, Yasutoshi Kuboki, Masashi Wakabayashi, Shogo Nomura, Yuichi Mikamoto, Hikari Shima, Noriko Fujishiro, Tsukiko Higuchi, Akihiro Sato, Takeshi Kuwata, Kohei Shitara
BACKGROUND: Pembrolizumab, an anti-PD-1 antibody, results in tumour response in around 15% of patients with advanced gastric cancer who have a PD-L1 combined positive score of at least 1. Lenvatinib, a multikinase inhibitor of VEGF receptors and other receptor tyrosine kinases, substantially decreased tumour-associated macrophages and increased infiltration of CD8 T cells, resulting in enhanced anti-tumour activity of PD-1 inhibitors in an in-vivo model. We aimed to assess the combination of lenvatinib plus pembrolizumab in patients with advanced gastric cancer in a phase 2 study...
June 23, 2020: Lancet Oncology
https://read.qxmd.com/read/32589865/lenvatinib-and-pembrolizumab-in-advanced-gastric-cancer
#6
Stefano Cascinu
No abstract text is available yet for this article.
June 23, 2020: Lancet Oncology
https://read.qxmd.com/read/32563279/cancer-and-the-microbiome
#7
Ashray Gunjur
No abstract text is available yet for this article.
June 18, 2020: Lancet Oncology
https://read.qxmd.com/read/32553118/berzosertib-plus-gemcitabine-versus-gemcitabine-alone-in-platinum-resistant-high-grade-serous-ovarian-cancer-a-multicentre-open-label-randomised-phase-2-trial
#8
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, Richard T Penson, Susan T Schumer, L Austin Doyle, Elizabeth K Lee, Elise C Kohn, Linda R Duska, Marta A Crispens, Alexander B Olawaiye, Ira S Winer, Lisa M Barroilhet, Siqing Fu, Michael T McHale, Russell J Schilder, Anniina Färkkilä, Dipanjan Chowdhury, Jennifer Curtis, Roxanne S Quinn, Brittany Bowes, Alan D D'Andrea, Geoffrey I Shapiro, Ursula A Matulonis
BACKGROUND: High-grade serous ovarian cancers show increased replication stress, rendering cells vulnerable to ATR inhibition because of near universal loss of the G1/S checkpoint (through deleterious TP53 mutations), premature S phase entry (due to CCNE1 amplification, RB1 loss, or CDKN2A mRNA downregulation), alterations of homologous recombination repair genes, and expression of oncogenic drivers (through MYC amplification and other mechanisms). We hypothesised that the combination of the selective ATR inhibitor, berzosertib, and gemcitabine could show acceptable toxicity and superior efficacy to gemcitabine alone in high-grade serous ovarian cancer...
June 15, 2020: Lancet Oncology
https://read.qxmd.com/read/32539942/covid-19-in-patients-with-thoracic-malignancies-teravolt-first-results-of-an-international-registry-based-cohort-study
#9
Marina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, Annalisa Trama, Valter Torri, Francesco Agustoni, Javier Baena, Giuseppe Banna, Rossana Berardi, Anna Cecilia Bettini, Emilio Bria, Matteo Brighenti, Jacques Cadranel, Alessandro De Toma, Claudio Chini, Alessio Cortellini, Enriqueta Felip, Giovanna Finocchiaro, Pilar Garrido, Carlo Genova, Raffaele Giusti, Vanesa Gregorc, Francesco Grossi, Federica Grosso, Salvatore Intagliata, Nicla La Verde, Stephen V Liu, Julien Mazieres, Edoardo Mercadante, Olivier Michielin, Gabriele Minuti, Denis Moro-Sibilot, Giulia Pasello, Antonio Passaro, Vieri Scotti, Piergiorgio Solli, Elisa Stroppa, Marcello Tiseo, Giuseppe Viscardi, Luca Voltolini, Yi-Long Wu, Silvia Zai, Vera Pancaldi, Anne-Marie Dingemans, Jan Van Meerbeeck, Fabrice Barlesi, Heather Wakelee, Solange Peters, Leora Horn
BACKGROUND: Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are thought to be particularly susceptible to COVID-19 given their older age, smoking habits, and pre-existing cardiopulmonary comorbidities, in addition to cancer treatments. We aimed to study the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with thoracic malignancies...
June 12, 2020: Lancet Oncology
https://read.qxmd.com/read/32539941/racism-discrimination-and-the-practice-of-oncology
#10
EDITORIAL
The Lancet Oncology
No abstract text is available yet for this article.
June 12, 2020: Lancet Oncology
https://read.qxmd.com/read/32534633/recommendations-for-head-and-neck-surgical-oncology-practice-in-a-setting-of-acute-severe-resource-constraint-during-the-covid-19-pandemic-an-international-consensus
#11
REVIEW
Hisham Mehanna, John C Hardman, Jared A Shenson, Ahmad K Abou-Foul, Michael C Topf, Mohammad AlFalasi, Jason Y K Chan, Pankaj Chaturvedi, Velda Ling Yu Chow, Andreas Dietz, Johannes J Fagan, Christian Godballe, Wojciech Golusiński, Akihiro Homma, Sefik Hosal, N Gopalakrishna Iyer, Cyrus Kerawala, Yoon Woo Koh, Anna Konney, Luiz P Kowalski, Dennis Kraus, Moni A Kuriakose, Efthymios Kyrodimos, Stephen Y Lai, C Rene Leemans, Paul Lennon, Lisa Licitra, Pei-Jen Lou, Bernard Lyons, Haitham Mirghani, Anthonny C Nichols, Vinidh Paleri, Benedict J Panizza, Pablo Parente Arias, Mihir R Patel, Cesare Piazza, Danny Rischin, Alvaro Sanabria, Robert P Takes, David J Thomson, Ravindra Uppaluri, Yu Wang, Sue S Yom, Yi-Ming Zhu, Sandro V Porceddu, John R de Almeida, Chrisian Simon, F Christopher Holsinger
The speed and scale of the global COVID-19 pandemic has resulted in unprecedented pressures on health services worldwide, requiring new methods of service delivery during the health crisis. In the setting of severe resource constraint and high risk of infection to patients and clinicians, there is an urgent need to identify consensus statements on head and neck surgical oncology practice. We completed a modified Delphi consensus process of three rounds with 40 international experts in head and neck cancer surgical, radiation, and medical oncology, representing 35 international professional societies and national clinical trial groups...
June 11, 2020: Lancet Oncology
https://read.qxmd.com/read/32534632/new-advances-in-prostate-cancer-screening-and-monitoring
#12
Elizabeth Gourd
No abstract text is available yet for this article.
June 11, 2020: Lancet Oncology
https://read.qxmd.com/read/32511985/2020-asco-virtual-annual-meeting
#13
David Collingridge
No abstract text is available yet for this article.
June 5, 2020: Lancet Oncology
https://read.qxmd.com/read/32511984/developing-anti-cd19-antibody-based-combinations-in-lymphoma
#14
John Kuruvilla
No abstract text is available yet for this article.
June 5, 2020: Lancet Oncology
https://read.qxmd.com/read/32511983/tafasitamab-plus-lenalidomide-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-l-mind-a-multicentre-prospective-single-arm-phase-2-study
#15
Gilles Salles, Johannes Duell, Eva González Barca, Olivier Tournilhac, Wojciech Jurczak, Anna Marina Liberati, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Marc André, Nagesh Kalakonda, Martin Dreyling, Johannes Weirather, Maren Dirnberger-Hertweck, Sumeet Ambarkhane, Günter Fingerle-Rowson, Kami Maddocks
BACKGROUND: Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation have poor outcomes and few treatment options. Tafasitamab (MOR208) is an Fc-enhanced, humanised, anti-CD19 monoclonal antibody that has shown preclinical and single-agent activity in patients with relapsed or refractory B-cell malignancies. Preclinical data suggested that tafasitamab might act synergistically with lenalidomide. We aimed to assess the antitumour activity and safety of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for autologous stem-cell transplantation...
June 5, 2020: Lancet Oncology
https://read.qxmd.com/read/32511982/a-new-approach-to-refractory-gastrointestinal-stromal-tumours-with-diverse-acquired-mutations
#16
Toshirou Nishida, Toshihiko Doi
No abstract text is available yet for this article.
June 5, 2020: Lancet Oncology
https://read.qxmd.com/read/32511981/ripretinib-in-patients-with-advanced-gastrointestinal-stromal-tumours-invictus-a-double-blind-randomised-placebo-controlled-phase-3-trial
#17
Jean-Yves Blay, César Serrano, Michael C Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L Jones, Steven Attia, Gina D'Amato, Ping Chi, Peter Reichardt, Julie Meade, Kelvin Shi, Rodrigo Ruiz-Soto, Suzanne George, Margaret von Mehren
BACKGROUND: Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge for patients with advanced gastrointestinal stromal tumours. We compared the efficacy and safety of ripretinib, a switch-control tyrosine kinase inhibitor active against a broad spectrum of KIT and PDGFRA mutations, with placebo in patients with previously treated, advanced gastrointestinal stromal tumours...
June 5, 2020: Lancet Oncology
https://read.qxmd.com/read/32479790/clinical-characteristics-and-risk-factors-associated-with-covid-19-disease-severity-in-patients-with-cancer-in-wuhan-china-a-multicentre-retrospective-cohort-study
#18
Jianbo Tian, Xianglin Yuan, Jun Xiao, Qiang Zhong, Chunguang Yang, Bo Liu, Yimin Cai, Zequn Lu, Jing Wang, Yanan Wang, Shuanglin Liu, Biao Cheng, Jin Wang, Ming Zhang, Lu Wang, Siyuan Niu, Zhi Yao, Xiongbo Deng, Fan Zhou, Wei Wei, Qinglin Li, Xin Chen, Wenqiong Chen, Qin Yang, Shiji Wu, Jiquan Fan, Bo Shu, Zhiquan Hu, Shaogang Wang, Xiang-Ping Yang, Wenhua Liu, Xiaoping Miao, Zhihua Wang
BACKGROUND: COVID-19 has spread globally. Epidemiological susceptibility to COVID-19 has been reported in patients with cancer. We aimed to systematically characterise clinical features and determine risk factors of COVID-19 disease severity for patients with cancer and COVID-19. METHODS: In this multicentre, retrospective, cohort study, we included all adult patients (aged ≥18 years) with any type of malignant solid tumours and haematological malignancy who were admitted to nine hospitals in Wuhan, China, with laboratory-confirmed COVID-19 between Jan 13 and March 18, 2020...
May 29, 2020: Lancet Oncology
https://read.qxmd.com/read/32479789/lockdown-poses-new-challenges-for-cancer-care-in-india
#19
Dinesh C Sharma
No abstract text is available yet for this article.
May 29, 2020: Lancet Oncology
https://read.qxmd.com/read/32479788/poor-clinical-outcomes-for-patients-with-cancer-during-the-covid-19-pandemic
#20
Liang V Tang, Yu Hu
No abstract text is available yet for this article.
May 29, 2020: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"